Metanephrine negative pheochromocytoma: a rare case report of dopamine-secreting tumor in an adolescent neurofibromatosis type 1 patient
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Pheochromocytoma (PCC) occurs in 4% of pediatric neurofibromatosis type 1 (NF1) patients and is characterized by epinephrine and norepinephrine secretion. Herein, we report the first case of dopamine-secreting PCC in a 13-year-old patient with NF1. A left adrenal mass was incidentally found on abdominal computed tomography (CT) during hypertension workup. Fractionated 24-hour urine metanephrine excretion was normal, but urine dopamine level was elevated. Focal 123I-metaiodobenzylguanidine uptake was observed on single-photon emission tomography/CT (SPECT/CT). Surgery was delayed due to small tumor size, vague symptoms, and increased dopamine level. After 6 months, focal significant uptake of the lesion on 6‐[18F]fluoro‐L‐3,4‐dihydroxyphenylalanine (18F-FDOPA) PET/CT increased and tumor size increased on abdominal CT. Laparoscopic resection was performed, and the mass was histologically confirmed as PCC. Currently, the vital signs of the patient are stable, urine dopamine level is normal, and there is no abnormal uptake of 18F-FDOPA PET/CT. This study reports a rare case of dopamine-secreting PCC. A multidisciplinary approach and focused examination are needed in metanephrine-negative, high-risk PCC patients.
Abstract
Pheochromocytoma (PCC) occurs in 4% of pediatric neurofibromatosis type 1 (NF1) patients and is characterized by epinephrine and norepinephrine secretion. Herein, we report the first case of dopamine-secreting PCC in a 13-year-old patient with NF1. A left adrenal mass was incidentally found on abdominal computed tomography (CT) during hypertension workup. Fractionated 24-hour urine metanephrine excretion was normal, but urine dopamine level was elevated. Focal 123I-metaiodobenzylguanidine uptake was observed on single-photon emission tomography/CT (SPECT/CT). Surgery was delayed due to small tumor size, vague symptoms, and increased dopamine level. After 6 months, focal significant uptake of the lesion on 6‐[18F]fluoro‐L‐3,4‐dihydroxyphenylalanine (18F-FDOPA) PET/CT increased and tumor size increased on abdominal CT. Laparoscopic resection was performed, and the mass was histologically confirmed as PCC. Currently, the vital signs of the patient are stable, urine dopamine level is normal, and there is no abnormal uptake of 18F-FDOPA PET/CT. This study reports a rare case of dopamine-secreting PCC. A multidisciplinary approach and focused examination are needed in metanephrine-negative, high-risk PCC patients.
참고문헌 (20)
- Havekes B, "Update on pediatric pheochromocytoma", Pediatr Nephrol, 24, pp.943~950 (2009)
- Neumann HP, "Germ-line mutations in nonsyndromic pheochromocytoma", N Engl J Med, 346, pp.1459~1466 (2002)
- Londe S, "Causes of hypertension in the young", Pediatr Clin North Am, 25, pp.55~65 (1978)
- Ferner RE, "Guidelines for the diagnosis and management of individuals with neurofibromatosis 1", J Med Genet, 44, pp.81~88 (2007)
- Gutmann DH, "The neurofibromatoses : when less in more", Hum Mol Genet, 10, pp.747~755 (2001)
- Zöller ME, "Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population", Cancer, 79, pp.2125~2131 (1997)
- Walther MM, "von Recklinghausen's disease and pheochromocytomas", J Urol, 162, pp.1582~1586 (1999)
- Bausch B, "Long-term prognosis of patients with pediatric pheochromocytoma", Endocr Relat Cancer, 21, pp.17~25 (2013)
- Yasunari K, "A dopamine-secreting pheochromocytoma", J Cardiovasc Pharmacol, 36, pp.S75~S77 (2000)
- Foo SH, "Dopaminesecreting phaeochromocytomas and paragangliomas : clinical features and management", Singapore Med J, 51, pp.e89~e93 (2010)
- Proye C, "Dopamine-secreting pheochromocytoma:an unrecognized entity? Classification of pheochromocytomas according to their type of secretion", Surgery, 100, pp.1154~1162 (1986)
- 박정규, "도파민을 분비하는 크롬친화세포종 1예", Endocrinology and Metabolism, 27(2), pp.159~162 (2012), 대한내분비학회[DOI]
- Dubois LA, "Dopamine-secreting pheochromocytomas : in search of a syndrome", World J Surg, 29, pp.909~913 (2005)
- Eisenhofer G, "Biochemical and clinical manifestations of dopamine-producing paragangliomas : utility of plasma methoxytyramine", J Clin Endocrinol Metab, 90, pp.2068~2075 (2005)
- Tam V, "The importance of the interpretation of urine catecholamines is essential for the diagnosis and management of patient with dopamine-secreting paraganglioma", Ann Clin Biochem, 42, pp.73~77 (2005)
- Shotaro M, "Dopamine-sereting pheochromocytoma and paraganglioma", J Endocr Soc, 5, pp.brab163~ (2021)
- Ito Y, "The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma", World J Surg, 16, pp.759~763 (1992)
- Lenders JW, "Pheochromocytoma and paraganglioma : an endocrine society clinical practice guideline", The J Clin Endocrinol Metab, 99, pp.1915~1942 (2014)
- 이은정, "신경내분비 종양에서 PET의 이용", Endocrinology and Metabolism, 22(6), pp.397~406 (2007), 대한내분비학회
- Imani F, "18F-FDOPA PET and PET", CT accurately localize pheochromocytomas, 2009, pp.50, 513~519